Skip to main content

Table 3 End-of-follow-up findings in Groups 1 and 2

From: Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes

  Group 1 PEGV Group 2 PEGV?+?SSA
Patients – n (%) 35 (56.4) 27 (43.6)
Duration (mo.) of PEGV therapy – median (range) 51 (15–72) 30 (6–72)*
Final weekly PEGV dose (mg) – median (range) 105 (70–210) 140 (70–280)
Final daily PEGV dose (mg)   
10 mg – n (%) 10 (28.6) 11(40.7)
15 mg – n (%) 11 (31.4) 2 (7.4)
20 mg – n (%) 9 (25.7) 8 (29.6)
25 mg – n (%) 1 (2.8) 1 (3.7)
30 mg – n (%) 4 (11.4) 4 (14.8)
40 mg – n (%) 0 (0) 1 (3.7)
Group mean (±SD) 16.8 (±6.3) 17.9 (±8.4)
Group median (range) 15 (10–30) 20 (10–40)
Subgroup with IGF-I normalization at end of follow-up 15 (10–30) 10 (10–30)
Subgroup with abnormal IGF-I levels at end of follow-up 15 (10–20) 20 (10–40)*#
Pts. requiring dose reduction during follow-up a – n (%) 5 (14.3) 4 (14.8)
Pts. with IGF-I normalization at any time during follow-up b – n (%) 29 (82.8) 18 (66.7)
Pts. with IGF-I normalization at end of follow-up – n (%) 28 (80) 15 (55.5)*
Final IGF-I levels   
μg/L,Median (range) 212 (110–1216)# 291 (150–1015)*#
SDS (range) 1.0 (−0.5–14.1)# 1.9 (−0.4–9.8)*#
μg/L,Mean (±SD) 269 (± 203) 372 (± 216)*#
Significant growth of (residual) adenoma - n (%) 0 (0) 1 (3.7)
Increase of liver enzymes - n (%) 5 (14.3) 3 (11.1)
Injections site events - n (%) 1 (2.9) 1 (3.7)
  1. a For these patients alone, final doses do not necessarily correspond to maximal doses.
  2. b Includes pts. whose IGF-I levels were not normalized at the end of follow-up.
  3. * p?<?0.05 vs. Group 1; #?=?p?<?0.05 vs. baseline IGF-I levels.
  4. The results are shown as median (range) or number (percent), unless otherwise specified. Systeme Internationale conversion factors: IGF-I (μg/L) X 0.131?=?nmol/liter.